Shirley Nagel, MD
Internal Medicine · Mount Dora, FLNPI 1043213366
Payments from drug & device makers
Across 1,026 payments — averaging $4211.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3.6M
- AbbVie$345K
- Astrazeneca UK Limited$149K
- Novo Nordisk AS$101K
- Pfizer$95K
- AstraZeneca$52K
- plus $28K from 30 others
Across 6 payments — averaging $61,064 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$366K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 24 | $3,550,937 |
| AbbVie(2 entities) | 52 | $345,015 |
| Astrazeneca UK Limited | 1 | $148,700 |
| Novo Nordisk AS | 742 | $101,343 |
| Pfizer | 34 | $95,294 |
| AstraZeneca | 23 | $52,087 |
| Chiesi USA, Inc. | 8 | $25,592 |
| Novo Nordisk | 25 | $345 |
| Amgen | 18 | $282 |
| GSK | 16 | $243 |
| Boehringer Ingelheim | 22 | $155 |
| Dexcom, Inc. | 6 | $121 |
| Sanofi-aventis U.S. LLC | 5 | $86 |
| Merck | 6 | $85 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $75 |
| Lilly USA, LLC | 5 | $72 |
| Novartis | 4 | $57 |
| Therapeuticsmd, Inc. | 3 | $52 |
| Johnson & Johnson | 3 | $48 |
| Revance Therapeutics, Inc. | 1 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Amneal Pharmaceuticals LLC | 2 | $34 |
| Bayer | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $30 |
| Astellas Pharma US Inc | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Millicent US Inc | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Vistapharm, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Abbott | 1 | $13 |
How this compares
$4,321,003 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Mount Dora
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.